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Abstract
There are numerous downstream consequences of marketed drugs like
antineoplastic agents on the gut microbiome, an effect that is suggested to contribute
to adverse event profiles and may also influence drug responses. In cancer, progress
is needed toward modulation of the host microbiome to prevent off-target side
effects of drugs such as gastrointestinal mucositis that result from gut dysbiosis. The
objective of this study was evaluation of the bioactivity of a supplement consisting
of capsules with a blend of 9 probiotic organisms of the genera Lactobacillus and
Bifidobacterium plus 10 digestive enzymes, in protecting the human gastrointestinal
tract from chemotherapy and an antibiotic. We used the Simulator of Human Intestinal
Microbial Ecosystem (SHIME) model, an in vitro model of a stable colon microbiota,
and introduced 5-fluorouracil (5-FU) and vancomycin as microbiome-disrupting drugs.
The probiotic with digestive enzymes supplement, added in capsules at in vivo doses,
improved fermentation activity in the colon reactors and accelerated the recovery of
microbial populations following 5-FU/vancomycin treatment. The supplement restored
the Bacteroidetes to Firmicutes ratios in the colon reactors, increased the diversity
of microbiota, and induced the production of microbial metabolites that elicited antiinflammatory cytokines in an in vitro model of intestinal inflammation. In the proximal
colon, preventative administration of the supplement resulted in full recovery of the
gut microbial community after cessation of 5-FU and vancomycin treatment. These
results identify a probiotic with digestive enzymes formulation that protects against
drug-induced gut dysbiosis, highlighting its potential utility as a component of routine
cancer care.

Introduction

Proteobacteria [1]. Metagenomic analyses show that
changes in the relative abundance of the two dominant
bacterial divisions, the Bacteroidetes and the Firmicutes,
represent functional indicators of the metabolic potential
of the gut microbiota, as demonstrated in experiments
comparing microbiota in obese vs. lean animals [2].
Specifically, experiments have shown that obese mice had a
50% reduction in Bacteroidetes and a proportional increase

The microbiome in the human gut is composed
of 500–1000 distinct bacterial species and up to 1014
total bacteria that are responsible for not only intestinal
health but also for regulation of the immune system.
The human gut microbiome is dominated by four main
phyla: Firmicutes, Bacteroidetes, Actinobacteria, and
www.oncotarget.com
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the cancer patient’s immune system, rely on a degree of
endogenous immunity for their effectiveness, which is
shown in several recent papers to be heavily influenced
by the intestinal microbiome. For example, gut dysbiosis,
evaluated based on stool samples, predicted resistance to
immunotherapeutic interventions in melanoma patients
[13]. Low diversity of commensal microorganisms
was also associated with immune suppression in cancer
patients [14]. Also, in a study of the anti-cancer effects of
anti-PD1 or anti-PD-L1 checkpoint inhibitor antibodies,
Bifidobacteria, a common probiotic strain, were found to
be abundant in the colons of experimental animals that
exhibited effective immunity against melanoma [15].
These lines of evidence provide testimony to the impact
that the healthy gut microbiome has for cancer patients’
clinical outcomes. Specific therapeutics are also directly
toxic to the gut microbiome and compromise patients’
recovery, notably, chemotherapeutic agents that can cause
several side effects with gastrointestinal (GI) mucositis
being one of the most frequent. Broadly speaking,
chemotherapeutic agents cause changes in the microbiome
that compromise energy metabolism, cause inflammation,
and underlie the adverse events and poor quality of life of
patients undergoing treatment. An example that has been
studied is 5-fluorouracil (5-FU), first line agent for the
treatment of metastatic colorectal agent, and a causative
agent of severe colonic mucositis indicated by weight loss,
diarrhea, bloody stool, shortened colon, and infiltration
of inflammatory cells [16]. 5-FU diminishes bacterial
richness and diversity in the gut, leading to reduced
overall abundance of important phyla involved in normal
microbial metabolism [16]. In fact, causal relationships
are established between 5-FU-induced perturbations of the
gut microbiota, the preponderance of pro-inflammatory
cytokines in the intestinal milieu, and adverse events
experienced by patients [16]. In another report that
is of particular relevance to the present study, fecal
microbiome transplantation was used to reverse antibiotic
(ampicillin) and 5-FU-induced gut dysbiosis in a mouse
model. Specifically, restoring the intestinal microbial
composition to a healthy state by fecal microbiome
transplantation successfully restored microbial diversity
and richness, increased the composition of species known
to exhibit anti-inflammatory actions such as Lactobacillus,
and a coordinate reduction in known pathogenic strains
[17]. Other drugs that are used in the armamentarium
for cancer patients have also been proven to cause gut
dysbiosis. Oral vancomycin, an antibiotic, is the mainstay
of therapy for severe infections produced by Clostridium
difficile, the most prevalent cause of healthcareassociated infectious diarrhea in developed countries.
In cancer patients, bacterial infections occur through
diagnostic and therapeutic procedures, for example, due
to placement of central venous catheters, and may have
particularly serious consequences owing to the underlying

in Firmicutes as compared to lean mice [3]. It is also
interesting that this intestinal microbiota alteration in ratios
of these phyla in obese subjects is associated with local and
systemic inflammation [4]. Indeed, in the gut microbiome,
the Bacteroidetes to Firmicutes ratio is regarded to be
of significant relevance in diverse conditions that are
associated with inflammation, including not only obesity
[5], but also in aging [6], irritable bowel syndrome [7],
and colon cancer [8]. In these cases, the decreased ratios
of Bacteroidetes to Firmicutes were modulated in response
to treatment strategies for example, by weight loss [5]. In
another example, probiotic feeding was used to ameliorate
the gut dysbiosis caused by a high-fat diet in experimental
animals, marked by recovery of Bacteroidetes and a
proportionate reduction in Firmicutes [9]. Of particular
relevance to the present subject matter, colorectal cancer
is marked by gut dysbiosis including reduced microbial
diversity in the feces of patients than controls [1], and
in tumor tissue compared vs. with areas of the mucosa
at least 10 cm away [10]. Among other differences, a
taxonomy based analysis of the gut microbiome showed
that Firmicutes was significantly more abundant in the
gut microbiota of cancerous tissues than that of adjacent
non-cancerous tissues [11]. The mechanisms behind
how these specific compositional changes in microbiota
contribute to disease are not fully understood. The shortchain fatty acids acetate and propionate are the main
fermentation products of the Bacteroidetes phylum while
butyrate is mainly produced by Firmicutes. However,
despite the proportional increases in Firmicutes in colon
cancer, butyrate concentrations, which functions in many
contexts including mitigating inflammation, are decreased
during colon carcinogenesis; therefore, it is possible that
specific beneficial species within this phylum may be less
predominant. Indeed, studies have shown that strains of
Lactobacillus (Phylum: Firmicutes) and Bifidobacterium
(Phylum: Actinobacteria) are diminished in colorectal
cancer [1]. These common probiotic bacteria are lactate
acid producers that are involved in anti-inflammatory
responses, anti-cancer activity, and pathogen exclusion
from gut colonization [1]. There is also a relationship
between the lactic acid bacteria and the butyrate producers
since the latter utilize lactate [12]. On this basis, there
are numerous mechanisms by which gut microbiota
dysbiosis leads to increased permeability, aberrant immune
activation, and chronic inflammation, all of which can
contribute to colorectal cancer initiation and progression
[1]. This information raises the question as to whether
specific probiotic formulations can be used to restore
the microbial composition and the beneficial microbial
metabolites in the gut
Intestinal microorganisms may determine the
outcome of cancer treatments as well as being themselves
affected by the treatments. Immunotherapeutic drugs, such
as checkpoint inhibitor antibodies designed to unmask
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Results

immunosuppression. During vancomycin therapy, most
intestinal microbiota genera are depleted [18]. The
rate of recovery of the microbiota following cessation
from vancomycin determines whether the individual is
subsequently susceptible to intestinal colonization by
pathogenic bacteria. Since the duration of gut dysbiosis is a
critical factor in managing adverse events of the treatment,
evaluation of putative therapies such as probiotics should
include monitoring the microbiota dynamics.
On the basis of this evidence, it has been widely
suggested that modulation of the gut microbiome may
be a useful therapeutic approach for improving the toxic
side effects of cancer treatments, thereby possibly altering
the trajectory of cancer. While a range or individual
probiotic microorganisms or other supplements have
been widely touted as having the capacity to modulate
the gut microbiome, the challenge in the field has been
the lack of validation of specific products. This is of
particular significance for indications where patients are
immunocompromised and undergoing treatment with
cytotoxic agents since it has even been suggested that
probiotics could induce bacteremia in certain populations
[19–25]. Therefore, the potential utility of probioticcontaining supplements for specific indications remains
unleveraged as a preventative means for offsetting
adverse events associated with cancer therapeutics and for
improving patients’ outcomes.
To address the need for a probiotic formulation
that protects against gut dysbiosis, this study evaluated a
proprietary blend of 9 probiotic organisms of the genera
Lactobacillus and Bifidobacterium, as well as 10 digestive
enzymes, for its efficacy at protecting the gastrointestinal
(GI) tract from the combined effects of 5-Fluorouracil
(5-FU) and vancomycin. The probiotic with digestive
enzymes supplement was evaluated using the Simulator
of Human Intestinal Microbial Ecosystem (SHIME),
a stable and reproducible in vitro system, to analyze its
influence chemotherapy plus antibiotic-induced changes
in microbial community activity and composition. The
present experiments provided a very stringent test for
the effects of this dietary supplement since the dysbiosis
created in this system represented a “two-hit” system
implementing two known microbiome-disrupting agents.
We report that the probiotic with digestive enzymes
supplement beneficially modulated the gut microbiome
under healthy conditions, and, most significantly,
improved recovery from 5-FU/vancomycin treatment
when administered to the SHIME system. Improvements
in microbial fermentation and attenuation of microbial
community dysbiosis elicited by 5-FU/vancomycin were
observed when the probiotic with digestive enzymes
supplement was given in a curative context (i.e. beginning
at the time of 5-FU/vancomycin treatment) but particularly
when given in a preventative context (i.e. starting prior to
5-FU/vancomycin).

www.oncotarget.com

Stability of the SHIME system for analysis of
the effects of a probiotic with digestive enzymes
supplement
The SHIME in vitro model system was designed
to create a stabilized microbiota community to allow
for collection of samples from the different intestinal
regions for analysis. Several microbial parameters were
monitored throughout the SHIME experiment to assess
the performance of the model and the basic changes in
the microbial community composition and activity due to
the probiotic with digestive enzymes supplement. After the
first week during the stabilization period, reproducibility
between each of the three SHIME units was determined
in order to confirm initiation of preventive treatment in
arm 3 of the SHIME. Reproducibility was confirmed
by analysis of SCFA levels, which were 85.8% similar
between the SHIME units. During the control period,
stability and reproducibility of the other two SHIME
units was determined. SCFA levels were stable within (on
average 86.8% similar between consecutive time points in
control period) and reproducible between the two SHIME
units (on average 86.8% similar), clearly indicating
stability and reproducibility of the microbial community
in terms of activity and composition. On this basis, it was
concluded that the effects that would be observed during
the subsequent treatment period could be attributable to
the probiotic with digestive enzymes supplement rather
than due to variability in the system itself.

Modulation of acid/base consumption by the
probiotic with digestive enzymes supplement
that is indicative of increased fermentation
activity
The consumption of acid and base reflects the
overall microbial activity in the SHIME reactors
representing the proximal and distal colon. Generally
speaking, there are distinct bacterial populations that
are native to the proximal and distal colon regions,
reflecting the different requirements for digestion in each
segment. Figure 1 depicts the average weekly acid/base
consumption during the control and treatment periods (i.e.
before and after 5-FU/vancomycin treatment). It should be
noted that the treatment period consisted of one week of
5-FU/vancomycin followed by three weeks without these
agents during which time recovery from 5-FU/vancomycin
could be monitored and compared for the experimental
treatment arms, as follows: 1) Control arm: receiving no
supplement; 2) Preventative arm that had already been
receiving the probiotic with digestive enzymes supplement
all through the previous stabilization and control periods;
and. 3; The curative arm that commenced supplementation
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with the probiotic with digestive enzymes supplement
only at the start of 5-FU/vancomycin administration.
As per Figure 1, 5-FU/vancomycin treatment
caused significant changes in reducing base consumption
the proximal colon but not the distal colon. In the
proximal colon, the addition of the probiotics with
digestive enzymes in both the curative and preventative
treatment arms significantly increased base consumption
in the proximal colon, countering the effects of 5-FU/
vancomycin. It should be noted that, in vivo, more bacterial
fermentation activity also occurs in the proximal colon
where substrate availability is higher [26]. In the distal
colon, the probiotic with digestive enzymes supplement
administered in the preventative arm also increased base
consumption, however, the 5-FU/vancomycin itself did
not significantly diminish this overall marker of metabolic
activity in the distal colon reactors.

Figure 2 shows the results for acetate, which is
produced by a range of gut microbes including Bacteroides
and Bifidobacteria, and exerts anti-inflammatory effects
[28]. Chemotherapy treatment resulted in a decrease
in acetate levels in both the proximal and distal colon
reactors. Although the recovery of acetate did not occur
in the proximal colon, preventative treatment with the
probiotic with digestive enzymes supplement increased
acetate in both control and 5-FU/vancomycin treatment
periods in the distal colon, suggesting that the pretreatment
with the supplement offsets the adverse impact of the
drugs on microbial metabolism.
In Figure 2, analysis of propionate concentrations
in the SHIME is also provided, a product of a diverse
group of metabolically active gut microbes, which
exerts anti-inflammatory effects in the colon as well as
systemically [28]. Once again, the expected reduction in
propionate in the SHIME reactors was observed in the
5-FU/vancomycin treatment period vs. the control period
in both the proximal and distal colon reactors. Here, both
the curative and preventative treatment arms with the
probiotic with digestive enzymes supplement resulted in
recovery of propionate levels relative to the control arm.
Figure 2 also shows the results for butyrate production
in the SHIME reactors, a primary product of Clostridium
clusters IV and XIVa (phylum Firmicutes). In vivo, butyrate
is largely metabolized by intestinal epithelial cells where it
serves as an energy source as well as a homeostatic factor
for normal colonic cell turnover and repair processes
[28]. In the SHIME, the expected result was obtained
whereby 5-FU/vancomycin treatment strongly decreased
butyrate levels in both the proximal and distal colon
reactors. Supplementation of the reactors with curative and
preventative administration of the probiotic with digestive

Improvements in Short Chain Fatty Acid (SCFA)
production by the probiotic with digestive
enzymes supplement, revealing significant
reversals of 5-FU/vancomycin-associated changes
The abundant SCFA, acetate, propionate and
butyrate, are generated by fermentation of dietary fibers by
gut microbiota. SCFA have a plethora of health-promoting
effects through their interactions with metabolite-sensing
G protein-coupled receptors on the gut epithelium and on
immune cells [27]. In these experiments, we monitored the
production of these three SCFA in the proximal and distal
colon reactors, comparing pre- and post-5-FU/vancomycin
treatments in the control (non-supplemented), curative,
and preventative arms that were treated with the probiotic
with digestive enzymes supplement.

Figure 1: The pH in the SHIME system is maintained by pre-set pH controllers at 5.6–5.9 in the proximal colon (PC)
and at 6.6 to 6.9 in the distal colon (DC) to ensure optimal environments for microbiota. As the reactors acidify during

changes in microbial activity, base is added. These results show acid and base consumption during control (C) and chemotherapy/antibiotic
treatment (TR) periods for the control (CTRL), curative (CUR), and preventative (PREV) arms with the probiotic with digestive enzymes
supplement. Results are shown for the reactors corresponding to the PC (A) and DC (B), and represent the average base/acid consumption
over the entire control (n = 6 measurement) and treatment (n = 12) period. (*) represents statistically significant differences between C and
TR (i.e. before and after 5-FU/vancomycin addition to the rea ctors, respectively). The different letters above the bars denote statistical
comparisons between the indicated groups where uppercase or lowercase letters define distinct comparator groups; p < 0.05 was considered
significant.
www.oncotarget.com
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enzymes supplement resulted in improved butyrate
production in the proximal and distal colon. Notably, the
differences between the curative and preventative arms were
not statistically different in either of the reactors.

the proximal and distal colon. These analyses focused on
looking at the rates of recovery of healthy microbiota
following the administration of 5-FU/vancomycin during
treatment week 1 (TR1; refer to Figures 3 and 4), where
5-FU/vancomycin was discontinued during the recovery
weeks spanning TR2-TR4 (Figures 3 and 4). Comparisons
were also conducted relative to the control period of the
SHIME where no 5-FU/vancomycin had been added but
the preventative arm was already receiving the probiotic
with digestive enzymes supplement, allowing its influence
on a healthy microbiome to be evaluated.
Specific strains of Lactobacillus and Bifidobacterium
strains exert beneficial influences on maintenance of
integrity of intestinal tissue in inflammatory circumstances

Changes in gut microbiota by the probiotic with
digestive enzymes supplement, revealing an
effect in countering 5-FU/vancomycin-induced
gut dysbiosis
To further evaluate the impact of the probiotic
with digestive enzymes supplement, the next series
of experiments utilized qPCR to identify changes the
microbial composition in the SHIME reactors representing

Figure 2: Effect of curative and preventative administration of a probiotic with digestive enzymes supplement on
short chain fatty acid production in SHIME reactors corresponding to the proximal colon and distal colon. Average

acetate, propionate, and butyrate production, as indicated, over the control (C) (n = 6) and treatment (TR) (n = 12) periods for the control
(CTRL), curative (CUR), and preventative (PREV) arms given the probiotic with digestive enzymes supplement is presented. (*) represents
statistically significant difference relative to the preceding period. The different letters above the bars denote statistical comparisons
between the indicated groups where uppercase or lowercase letters are used to delineate the distinct comparator groups, and p < 0.05 was
interpreted as significant.
www.oncotarget.com
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and actions against toxicity of chemotherapeutic agents
including intestinal mucositis [29–33]. In addition to being
permanent genera of the human intestinal microbiota,
these strains are highly enriched in the probiotic plus
digestive enzymes supplement. We evaluated the SHIME
reactors for the presence of these lactate-producing
bacteria, the Lactobacillus and Bifidobacterium strains. In
Figure 3, data are shown for control and 5-FU/vancomycin
treatments among the different experimental arms that
received no supplement or either curative or preventative
administration of the probiotic with digestive enzymes
supplement. First, as we expected, the results showed
that 5-FU/vancomycin reduced the populations of these
bacteria in the SHIME. For Lactobacillus, after the 5-FU/
vancomycin treatment period during TR1 (Figure 3),
Lactobacillus levels recovered after administration of the
probiotic with digestive enzymes supplement, but also for
the negative control in both colon regions. Significantly
however, treatment with the supplement resulted in a
faster recovery as compared to the negative control that
lacked the supplement (Figure 3). For Bifidobacteria,

after cessation of 5-FU/vancomycin, the levels of these
microbes dropped drastically for the negative control
in both colon regions, but especially in the PC where
Bifidobacteria levels dropped below detection limit at
the end of the treatment period (Figure 3). Administration
of the probiotic with digestive enzymes supplement
resulted in a slight recovery of Bifidobacteria levels,
with no differences observed between the curative and
the preventive arms of supplementation. It should be
noted that, during the control periods (C1 and C2) prior
to 5-FU/vancomycin treatment, overall Lactobacilli and
Bifidobacteria did not increase in the PC or the DC.
We also assessed the composition of Bacteroidetes
and Firmicutes, the predominant phyla in the healthy human
gut, to determine how they are influenced by the probiotic
with digestive enzymes supplement in the SHIME. The
results showed that Bacteroidetes levels were particularly
depleted during the 5-FU/vancomycin treatment period.
Significantly, we observed that administration of the
probiotic with digestive enzymes supplement also
resulted in faster recovery of Bacteroidetes after 5-FU/

Figure 3: Analysis of modulation of the Lactobacillus and Bifidobacterium composition by the probiotic with digestive
enzymes supplement. The effect of a curative (CUR) and preventive (PREV) administration of the probiotic with digestive enzymes

supplement as compared to a control SHIME (CTRL) on luminal Lactobacillus (left panels) and Bifidobacterium (right panels) levels (16S
rDNA copies/mL) in the proximal (PC; top panels) and distal colon (DC; bottom panels). The data are represented for the control weeks
(C1, C2) and treatment weeks (TR1, TR2, TR3, and TR4. It should be noted that 5-FU/vancomycin was administered to the system in TR1
and discontinued in TR2–TR4. Preventative administration of the probiotic with digestive enzymes supplement was being administered
throughout the control periods (C1 and C2), while curative supplementation of the probiotic with digestive enzymes formulation was
initiated and maintained at TR1-TR4. (*) indicates statistically significant differences relative to the preceding period, while different letters
indicate a statistical difference between different treatments; p < 0.05.
www.oncotarget.com
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vancomycin (after TR1) as compared to the control arm,
an effect that was the greatest for the preventative arm
of supplementation over the curative arm (Figure 4).
Remarkably, the Bacteroidetes levels were restored to
control (pre-5-FU/vancomycin) levels during treatment
weeks 3 and 4. This finding supports the capacity of the
supplement to hasten the recovery of the gut microbiota
following 5-FU/vancomycin treatment with the lowest
levels observed in the colon reactors on treatment week 2
(TR2; Figure 4). Analysis of Firmicutes showed a more
modest depletion in response to 5-FU/vancomycin that
was evident at treatment week 1 (Figure 4), however, all
three arms (control, preventative, and curative) recovered
in the colon reactors after the treatment was discontinued.
Interestingly, as can be appreciated in the proximal colon
reactors, there was a faster recovery of Firmicutes in
the preventative and curative arms vs. the control arm.
This recovery was noted during TR2 and TR3 where the
probiotic with digestive enzymes supplement promoted
the rapid return to the Firmicutes levels in the control
period. Overall, these results show that the probiotic and

digestive enzymes supplement restores the Bacteroidetes to
Firmicutes ratios following 5-FU/vancomycin.

Increased diversity of the microbial community
is promoted by administration of the probiotic
with digestive enzymes supplement
16S-targeted Illumina sequencing was used whereby
amplified 16S rRNA marker gene sequences are clustered
into taxonomic units of bacteria. When the data had
been processed at the phylum and family levels, and
the Simpson diversity index was calculated. The lowest
possible value of the index is 1, representing a community
consisting of only one Operational Taxonomic Unit
(OTU). The highest possible value is the total number of
OTUs, and the higher the index, the larger the diversity
and the larger the evenness. Table 1 shows the Simpson
Diversity Index results to evaluate the impact of the
probiotic with digestive enzymes supplement on diversity
changes in the microbiota in the SHIME that are caused by
5-FU and vancomycin. In the distal colon, the supplement

Figure 4: Changes in the dominant phyla of beneficial gut microbes, Bacteriodetes and Firmicutes, by the probiotic
with digestive enzymes supplement. The effect of a curative (CUR) and preventive (PREV) administration of the probiotic with

digestive enzymes supplement as compared to a control SHIME (CTRL) on luminal Bacteroidetes, and Firmicutes levels (16S rDNA
copies/mL) in the proximal (PC; top panels) and distal colon (DC; bottom panels). The data are represented for the control weeks (C1,
C2) and treatment weeks (TR1, TR2, TR3, and TR4. It should be noted that 5-FU/vancomycin was administered to the system in TR1
and discontinued in TR2-TR4. Preventative administration of the probiotic with digestive enzymes supplement was being administered
throughout the control periods (C1 and C2), while curative supplementation of the probiotic with digestive enzymes formulation was
initiated and maintained at TR1-TR4. (*) indicates statistically significant differences relative to the preceding period, while different letters
indicate a statistical difference between different treatments; p < 0.05.
www.oncotarget.com
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Table 1: Changes in the diversity of microbiota resulting from curative or preventative administration of the probiotic
with digestive enzymes supplement
Control

Curative

Preventative

Control

Treatment

Control

Treatment

Control

Treatment

Proximal Colon

3.0

7.6

2.7

5.4

2.2

2.6

Distal Colon

7.5

7.5

7.5

9.2

11.5

11.2

Reciprocal Simpson Diversity Index in the lumen of the proximal and distal colon of the SHIME upon a curative (CUR) and
preventive (PREV) administration of the probiotic with digestive enzymes supplement was compared to a control SHIME
(CTRL) at the end of the control [control week 2 (C)] and treatment [treatment week 4 (TR4)] periods. The intensity of the
shading indicates the absolute diversity index, normalized for each of the environments (i.e. within each row).
given preventatively had the most significant impact
on increasing the microbial diversity. In the proximal
colon, the highest diversity was observed in the negative
control (i.e. no supplement) following recovery from
5-FU and vancomycin (TR4). Curative treatment with the
supplement also increased the microbial diversity in both
the proximal and distal colons.
Lastly, 16S-targeted Illumina sequencing was used
to evaluate the differences in microbial compositions at
the phylum level in the proximal and distal colons caused
by the probiotic with digestive enzymes supplement.

In Figure 5, the results show that the supplement did
indeed cause changes in the microbial communities. The
preventative treatment prior to 5-FU/vancomycin treatment
did not cause any major changes at the phylum level in the
proximal colon. However, in the distal colon, preventative
supplementation resulted in increases in abundance
of Actinobacteria and reductions in Bacteroidetes and
Proteobacteria.
Following 5-FU/vancomycin treatment, the
microbiome in the distal colon did not differ at the
phylum level for the control, curative or preventative arms

Figure 5: Addition of the probiotic with digestive enzymes supplement to the SHIME modulates the microbial
communities at the phylum level. Abundance (%) of the dominant phyla in the lumen of the proximal (PC) and distal colon (DC) of

the SHIME upon a curative (CUR) and preventive (PREV) administration of the probiotic with digestive enzymes supplement as compared
to control (CTRL) the end of the control week 2 (C) and treatment week 4 (TR) period.
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(Figure 5). In contrast, in the proximal colon, only
preventive administration of the probiotic with digestive
enzymes supplement resulted in full recovery of the gut
microbiota after cessation of 5-FU/vancomycin treatment,
mainly increasing the abundance of Bacteroidetes at
the expense of Proteobacteria as compared to the other
experimental arms. Collectively, these findings support
the most significant changes in beneficial microbial
communities as occurring in response to preventative
administration with the probiotic with digestive enzymes
supplement. However, it is plausible that a longer duration
of curative treatment with the supplement would afford
similar results as the preventative treatment.

of the probiotic with digestive enzymes supplement in the
face of 5-FU/vancomycin treatment.
The results of the Caco-2/THP-1 co-culture
experiments are provided in Figure 6. Measurement
of IL-6 was performed as known pro-inflammatory
signature of LPS-stimulated macrophages, and also of
colonic mucosal cells [36, 37]. The results showed that
preventative treatment with the probiotic with digestive
enzymes supplement generated microbial metabolites
in the proximal colon reactors that decreased IL-6
concentrations in the co-culture model as compared
to the control reactors that were not supplemented but
were treated with 5-FU/vancomycin. Thus, LPS-induced
inflammation was modulated by fermentation products
derived from reactors to which the supplement was
administered prior to treatment with 5-FU/vancomycin.
From the distal colon reactors, the SHIME suspensions
taken from the control period, during which baseline
microbial activities were monitored, and the treatment
period with 5-FU/vancomycin did not differ with respect
to the concentrations of IL-6 in the co-culture. Secondly,
we also monitored IL-10 production induced in the Caco2/THP-1 cultures as a representative anti-inflammatory
cytokine produced by macrophages during LPS
stimulation (Figure 6). One point of interest was that that
the metabolites from SHIME reactors following treatment
with 5-FU/vancomycin induced greater IL-10 production
than those from the control (baseline) period in the PC.
However, administration of the probiotic with digestive
enzymes supplement prior to 5-FU/vancomycin (i.e the
control period) generated metabolites in the PC with the
highest IL-10 inducing capabilities in the co-cultures.
In the DC, the results showed statistically significant
increases in IL-10 were generated in co-cultures given
SHIME suspensions from the preventative arm from
both the control period and 5-FU/vancomycin treatment
period. Collectively, the reductions in IL-6 and increases
in IL-10 observed in the Caco-2/THP-1 model of intestinal
inflammation containing SHIME suspensions suggest that
the probiotics with digestive enzymes supplement affects
the gut microbiome toward controlling inflammation.

Impact of the probiotic with digestive enzymes
supplement on cytokines in an in vitro model of
intestinal inflammation
We next asked how the probiotic with digestive
enzymes supplement alters the composition of bacterialderived metabolites having the potential to impact immune
function as a means of offsetting the negative effects of
5-FU/vancomycin. To this end, we leveraged an in vitro
model system that has been described as an ‘inflammatory
bowel disease-like’ model that uses Caco-2 (intestinal
epithelial like cells) and THP-1 macrophages [34]. Caco-2
cells originate from a human colon adenocarcinoma cell
line that can differentiate into mature, enterocyte-like cells
that are characterized by the formation of villi, presence
of tight junctions, and expression of apical brush border
enzymes, thereby recapitulating the colon [35]. THP-1
cells, derived from acute leukemia, differentiate into
macrophages upon culture with phorbol 12-myristate
13-acetate (PMA), and can then be activated toward a
highly pro-inflammatory phenotype upon treatment with
lipopolysaccharide (LPS). In the setup used here, Caco-2
cells were placed on top of PMA-treated THP-1 cells,
on the apical and basolateral sides of culture chambers,
respectively. Colonic suspensions collected from the
SHIME reactors, treated with the same regimens of
5-FU/vancomycin and probiotic with digestive enzymes
supplement as in the previous experiments, were added to
the apical side of the culture chambers containing Caco-2
cells. After 24 h of the apical pre-treatment of the Caco-2/
THP-1 co-cultures with the SHIME samples, the basolateral
supernatant was discarded and the THP cells were treated
with LPS to provide inflammatory signals. Subsequently,
after 6 hours of stimulation, cytokines were measured
from the basolateral side of the chamber containing the
THP-1 cells, which will have been affected indirectly by
signals from the Caco-2 cells or directly by the transport of
metabolites and molecules. In this manner, the interactions
between cells of the gut and the immune system can be
recapitulated in vitro. These experiments allow examination
of the influence of the microbial fermentations-derived
products following preventive and curative administration
www.oncotarget.com

Discussion
The objective of this study was to evaluate the
potential benefits of a proprietary probiotic with digestive
enzymes supplement in preventing the gut dysbiosis
caused a chemotherapy treatment and an antibiotic in a preclinical analysis of bioactivity. The test product contains
a blend of 9 probiotic organisms of the Lactobacillus and
Bifidobacterium genera, as well as 10 digestive enzymes
contained in capsules that were administered in an in vitro
system to recapitulate the gut microbiome using doses of
the product that would be administered clinically. Using
the SHIME model platform, where the gut microbiota can
be cultured under representative conditions of the different
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intestinal regions, we successfully demonstrated that the
probiotic with digestive enzymes supplement was capable
of modulating the effects of 5-FU/vancomycin when
administered in a preventative context. We also noticed
positive changes in the microbial activity and composition
using the probiotic with digestive enzymes supplement
added to the SHIME beginning at the same time as
5-FU/vancomycin (i.e. the curative arm), including the
production of metabolites that induced anti-inflammatory
cytokine production in the Caco-2/THP-1 model. Based on
studies that are ongoing, we believe that a longer duration
of curative supplementation than was performed in the
SHIME would have achieved at least a similar magnitude
of beneficial effects as the preventative arm.
The present study bridges the large gap that exists
between the extensive microbiome research taking place
and the lack of validation for specific products that are
on the market. To this point, one DNA-based analysis of

bifidobacterial species in commercial probiotic products
demonstrated that only one of sixteen tested products
matched the bifidobacterial label claim, and pill-to-pill
and lot-to-lot variation was observed [38]. The authors of
this study also pointed out that misidentified commercial
products, in addition to the lack of comparison between
strains or species, is a barrier to the ability of clinicians
to make informed decisions about what to prescribe.
Another point of discussion is that there is a great deal
of variability between products in terms of how many
viable, functional probiotic bacteria can be delivered to
the gut; therefore, testing of effectiveness of supplements
using advanced in vitro analysis is advisable [39]. Another
understudied area, which, to our knowledge, has not
been previously examined in pre-clinical studies, is a
supplement that combines probiotic microorganisms with
digestive enzymes. While digestive enzymes generally
serve to improve nutrient absorption in the gut, they also

Figure 6: Modulation of cytokine profiles in an in vitro model of intestinal inflammation by metabolites from SHIME
reactors treated with the probiotic with digestive enzymes supplement. Samples of SHIME suspensions were taken from

reactors with curative (CUR) and preventive (PREV) administration of the probiotic with digestive enzymes supplement as compared to a
control SHIME (CTRL; no supplement) from the control period (baseline microbial community prior to 5-FU/vancomycin) and treatment
period with 5-FU/vancomycin. Cytokine levels of IL-6 (A) and IL-10 (B) were measured 6 h after LPS treatment on the basolateral side
of the Caco2/THP-1 co-cultures after pre-treatment of the apical side for 24 h with the SHIME samples. The red dotted line corresponds
to the experimental control consisting of LPS. Data are plotted as the mean ± SEM. The chart (lower panel) outlines the corresponding
statistical analyses performed using two-way ANOVA with Dunnett’s multiple comparisons test. Significance is depicted where (*). (*), (**),
(***) and (****) represent p < 0.05, p < 0.01, p < 0.001 and p < 0.0001, respectively. Ns = non-specific; PC: proximal colon; DC: distal colon.
www.oncotarget.com

30928

Oncotarget

are expected to have a complementary or synergistic
role with the probiotic microbes. One study reported
that pancreatic enzyme supplementation to experimental
animals modified the intestinal microbiota, allowing
increased colonization of Lactobacillus strains in addition
to improving nutritional status [40]. In a study related
to microbial activities in the genital tract, amylase, a
glycogen-degrading enzyme, was found to allow for the
growth of certain Lactobacillus isolates in the glycogen
breakdown products that cannot grow in absence of the
enzyme [41]. These studies support a beneficial impact of
combining probiotics with digestive enzymes to improve
microbial metabolism in the gut.
Cancer patients undergoing chemotherapy, radiation
therapy or other drug treatments experience a plethora of
adverse events related to their treatments including nausea,
vomiting, diarrhea, and loss of appetite, leading to a lower
dietary intake, weight loss, and susceptibility to infections.
These symptoms can be directly linked to the disturbed
intestinal microbiome. During gut dysbiosis, parameters
such as water volume, ion concentrations, osmotic
pressure and pH are often abnormal, leading to growth of
bacteria that further contribute to homeostatic imbalances
and mediate aggressive inflammation [42]. This
inflammation damages the intestinal mucosa, reducing
the overall microbial diversity and allowing pathogenic
species to thrive in the gut. Indeed, pyrosequencing
studies have demonstrated that probiotics can afford a
5-fold decrease in the abundance of members of the genus
Fusobacterium [43], potential pathogens that are enriched
in the mucosal flora of colorectal cancer patients [44]. By
introducing missing microbial components, probiotics
are believed to directly antagonize enteric pathogens,
modulate innate or adaptive immunity, and strengthen
mucosal barrier function to alleviate gastrointestinal
symptoms [45]. Cancer cachexia, a metabolic disorder
characterized by anorexia and muscle wasting, represents
another unmet medical need. Interestingly, in an animal
model of leukemia that is characterized by cachexia,
administration of an oral probiotic to restore Lactobacillus
species reduced the expression of markers of atrophy in the
muscles as well as inflammatory cytokines including IL-6
[46]. Similarly, administration of prebiotics in a cachexia
model led to modulation of the gut microbiome, including
increases in beneficial strains such as Bifidobacterium,
which coincided with metabolic shifts in the periphery
and a delay in tumor-induced cachexia [47]. Conservation
of the gut microbiome may therefore improve not only
tumor- and treatment-associated changes the gut itself but
also systemic metabolic disturbances.
A separate and related issue is the role of the gut
microbiome in tumor initiation since there is abundant
evidence that chronic infection and the ensuing inflammation
are contributing factors to tumor initiation [48]. SCFA
promotes and maintains colonic epithelial health through
maintaining barrier function, suppressing tumorigenesis by
www.oncotarget.com

regulating DNA methylation and diminishing oxidative stress,
and inhibiting inflammation (Sun) It is plausible that dietary
changes or probiotic interventions may reduce the risk of
colorectal cancer, however, the potential impact of microbiome
modulating-strategies on tumorigenesis itself is not clear, and
awaits investigation for the probiotics with digestive enzymes
supplement that was the focus of the current study.
The limited evidence confirming the safety and
benefits of these products in human clinical studies has
led to a recommendation for cancer patients, who are
immunocompromised, to take only moderate doses of
dietary supplements or none at all [49]. Isolated case
reports have asserted that overt bacteremia can result from
the use of probiotics by immunocompromised patients.
Several cases of Lactobacillus and Bifidobacterium
bacteremia [19–25] as well as cases of sepsis associated
with Saccharomyces cerevisiae [50, 51], a probiotic strain
used the treatment and prevention of Clostridium difficileassociated diarrhea, have been reported to be associated
with probiotic intake by ICU patients and individuals
with immunodeficiency disorders. The amassed results
from 17 studies revealed 5 case reports of probioticassociated bacteremia or fungaemia based on blood culture
tests. Another analysis [52] concluded that “there remain
insufficient studies to assess the true effect of probiotics
in people with cancer. Meta-analysis suggests probiotics
may be beneficial but further studies are still required.
Improved reporting of outcomes and adverse events
in clinical trials are required to improve accuracy and
confidence of conclusions drawn in future updates.” With
respect to efficacy, another a recent meta-analysis carried
out to analyze data related to the efficacy and safety of
probiotics in people with cancer, the results compiled for
11 studies showed that probiotics may reduce the severity
and frequency of diarrhea in patients with cancer and may
reduce the requirement for anti-diarrheal medication,
however, the analysis showed that firm conclusions could
not be drawn with the available information [53]. We would
argue, and it is our approach, that research and clinical
studies need to be performed in a product-specific manner
to evaluate for a positive impact on the microbiome and for
efficacy for a particular indication. In sum, using a dynamic
model of the gut ecosystem, this report validates a probiotic
with digestive enzymes supplement as being beneficial for
countering microbial imbalances and maladaptation in the
gastrointestinal tract. These results provide an impetus for
clinical studies evaluating the curative and preventative
effects of this supplement against chemotherapy-associated
adverse events that stem from gut dysbiosis.

Materials and Methods
Probiotic with digestive enzymes supplement
The probiotic with digestive enzymes supplement
used herein comprises capsules is manufactured using
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proprietary methods and contains a blends of probiotics
(116.20 mg total weight); specifically, Bifidobacterium
infantis, Bifidobacterium bifidum, Lactobacillus
acidophilus, Lactobacillus salivarius, Lactobacillus
plantarum, Lactobacillus rhamnosus, Bifidobacterium
longum, Lactobacillus casei, Lactobacillus paracasei, and
digestive enzymes (272.65 mg total weight); specifically,
amylase, glucoamylase, lipase, bromelain, maltase,
lactase, hemicellulose, xylanase, papain, and invertase.
The capsules used herein are the same formulation
that would be administered in vivo. The product was
tested at an in vitro dose of 3 capsules/day before
chemotherapy/antibiotic treatments, and 4 capsules/day
during and after chemotherapy/antibiotic treatment (to be
described below). This corresponds to an in vivo dosage
of 6 capsules/day and 8 capsules/day before and after
chemotherapy/antibiotic treatment, respectively.

Accordingly, a TripleSHIME set-up was utilized
wherein the colon reactors were limited to two instead
of three to account for the additional test conditions
required; specifically, reactors corresponding to PC-DC
units (proximal and descending colon) instead of ACTC-DC units (ascending, transverse, and descending
colon).

Stages of the SHIME experiment
The stages of the experiment are described below
and also summarized in Table 2.
Stabilization period (Weeks 1 and 2)
After inoculation of the colon reactors with an
appropriate fecal sample, a two-week stabilization period
allowed the microbial community to differentiate in the
different reactors depending on the local environmental
conditions. During this period, the basic nutritional matrix
was provided to the SHIME to support diversity of the gut
microbiota originally present in the fecal inoculum. The
third arm of the SHIME setup (preventive arm; PREV),
already received 3 capsules/day during the stabilization
period (corresponding to an in vivo dose of 6 capsules/day).

Simulator of human intestinal microbial
ecosystem (SHIME) setup
ProDigest (Gent, Belgium) conducted the SHIME
experiments and analysis. Briefly, the SHIME system
consists of a series of double-jacketed vessels, simulating
the digestive compartments that are initially inoculated
with a fecal sample from a healthy adult donor using
methods described previously [54].
The typical reactor setup consists of a succession
of five reactors simulating the different parts of the
human gastrointestinal tract. The first two reactors
simulate different steps in food uptake and digestion, with
peristaltic pumps adding a defined amount of SHIME feed
(140 mL 3×/day) and pancreatic and bile liquid (60 mL 3×/
day), respectively to the stomach (V1) and small intestine
(V2) compartment and emptying the respective reactors
after specified intervals [54]. The last three compartments
simulate the large intestine. These reactors are continuously
stirred, and they have a constant volume and pH control.
Retention time and pH of the different vessels are chosen
in order to resemble in vivo conditions in the different parts
of the colon. Upon inoculation with fecal microbiota, these
reactors simulate the ascending (V3), transverse (V4) and
descending (V5) colon.
The present experiments employed an adapted
SHIME setup to accommodate the following three
treatment arms (vs. two arms that are typically compared
using this system):
Control Arm: Chemotherapy and antibiotics; no
supplement given.
Curative Arm: Chemotherapy and antibiotics;
probiotic with digestive enzymes supplement added at the
same time as the other agents.
Preventative Arm: Chemotherapy and antibiotics;
probiotic with digestive enzymes supplement added prior
to the other agents.

www.oncotarget.com

Control period (Weeks 3 and 4)
During this two-week reference period, the standard
SHIME nutrient matrix was further dosed to the model.
Analysis of samples in this period allows to determine the
baseline microbial community composition and activity in
the different reactors, which will be used as a reference
for evaluating the treatment effects. The third arm of the
SHIME setup (PREV), already received 3 capsules/day
during the control period (~ in vivo dose of 6 capsules/
day).
Treatment period (Weeks 5–8; 5-FU plus vancomycin
during Week 5)
During this four-week period, the SHIME reactor
was operated under nominal conditions, but each arm was
treated as follows. During the first week, all arms received
chemotherapy (10 μM of 5-fluorouracil (5-FU)) and
vancomycin treatment (62.5 mg/L of vancomycin). During
the subsequent weeks, it was considered a “recovery”
period from the effects of 5-FU and vancomycin. Arm 1
of the SHIME did not receive any additional treatment (i.e.
control arm; CTRL). Arm 2 of the SHIME received the
probiotic with digestive enzymes supplement (4 capsules/
day ~ in vivo dose of 8 capsules/day) at the start of the
chemotherapy administration (i.e. curative arm; CUR),
whereas addition of the supplement for arm 3 of the
SHIME was continued (at 4 capsules/day ~ in vivo dose of
8 capsules/day) (PREV).
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Table 2: Overview of treatment stages with 5-fluorouracil and vancomycin in the SHIME
Week 1
Stabilization

Week 2
Stabilization

Week 3
Control

Week 4
Control

Week 5
Treatment
5-FU/vancomycin

Analysis of the activity and composition of
microbiota in the SHIME

Week 7
Recovery
from
treatment

Week 8
Recovery
from
treatment

of diversity and evenness of the microbiota as described
previously [58]. An increase in the Simpson reciprocal
index reflects a diversity increase, with 1 being the lowest
possible number, and the number of bacterial species/
OTUs present in the sample being the maximal number.
The index will approach the maximal value when the OTU
distribution is more even. The higher the index, the larger
the diversity and the larger the evenness.

The following microbial parameters were monitored
throughout the entire SHIME experiment to evaluate the
performance of the model and/or to allow monitoring of
basic changes in the microbial community composition
and activity due to the probiotic with digestive enzymes
supplement.

In vitro analyses of immune markers

Microbial community activity

Caco-2 cells

The concentrations of SFCA; specifically, acetic
acid, propionic acid and butyric acid, were analyzed as
by-products of microbial metabolism. Each of these
parameters was measured three times/week. Briefly, SCFA
were extracted from samples with diethyl ether after the
addition of 2-methylhexanoic acid as an internal standard.
Extracts were analyzed using gas chromatography as
described previously [55]. The concentrations of lactate,
the precursor of SCFA, were also monitored using a
d-lactate/l-lactate kit (R-Biopharm, Mannheim, Germany),
according to the manufacturer’s protocols.

The co-culture experiment was performed as
previously described [34] Briefly, Caco-2 cells (HTB-37;
American Type Culture Collection) were seeded in 24-well
semi-permeable inserts (0.4 μm pore size) at a density of
1 × 105 cells/insert. Caco-2 monolayers were cultured
for 14 days, with three medium changes/week, until
a functional cell monolayer was obtained. Cells were
maintained in Dulbecco’s Modified Eagle Medium
(DMEM) containing 25 mM glucose and 4 mM glutamine
and supplemented with 10 mM HEPES and 20% (v/v)
heat-inactivated (HI) fetal bovine serum (FBS).

Microbial community composition

THP-1 cells

As part of the SHIME experiments, the following
groups were quantified via quantitative PCR (qPCR;
once/week): Bacteroidetes phylum, Firmicutes phylum,
Lactobacillus spp. and Bifidobacterium spp. as previously
reported [56].

THP1 cells (InvivoGen) were maintained in Roswell
Park Memorial Institute (RPMI) 1640 medium containing
11 mM glucose and 2 mM glutamine, supplemented with
10 mM HEPES, 1 mM sodium pyruvate and 10% (v/v)
HI-FBS. THP1 cells were seeded in 24-well plates at a
density of 5 × 105 cells/well and treated with 100 ng/mL
of PMA for 48 hours (h). PMA induces the differentiation
of the cells into macrophage-like cells.

16S-targeted Illumina sequencing
16S ribosomal RNA (rRNA) sequencing was used
to analyze samples from the SHIME reactors to identify
and compare the microorganisms using similar methods
as published elsewhere [57]. The Illumina sequencing
method was used to amplify microbial sequences until
a saturation level was reached. Information on a broad
spectrum of OTUs was obtained (>100 different of
the most dominant OTUs), however, the results were
presented as proportional values versus the total amount
of sequences within each sample, thus providing semiquantitative results. The methodology used primers that
span 2 hypervariable regions (V3–V4) of the 16S rDNA.
Using a paired sequencing approach, sequencing of 2×250
bp resulted in 424 bp amplicons.
To provide an ecological interpretation of these data,
the Simpson reciprocal index was calculated as a measure
www.oncotarget.com

Week 6
Recovery
from
treatment

Caco-2/THP-1 co-cultures
To mimic the interface between host immune cells
and the fermentation products of the gut microbiome,
in vitro experiments were conducted based on previous
studies by Satsu and colleagues [59]. In this setup, the
colonic suspensions collected from the SHIME are
brought in contact with the apical side of the co-cultures
(i.e. Caco-2 cells). The effects observed on the basolateral
chamber where the THP-1 cells reside are mediated
indirectly by signals produced by the Caco-2 cells and/or
by the transport of micro- and macro-molecules.
Briefly, the apical compartment containing Caco2 cells was filled with sterile-filtered (0.22 μm) colonic
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